Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $9.32 to $9.87
• 50-Day Range: $9.67 to $15.76
• 52-Week Range: $4.88 to $19.58
• Volume: 77,987 shs
• Average Volume: 48,896 shs
• Market Capitalization: $211.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.80
• Consensus Rating: Buy

AARD Stock Analysis - Frequently Asked Questions

How have AARD shares performed this year?

Aardvark Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, AARD shares have decreased by 26.5% and is now trading at $9.77.

How were Aardvark Therapeutics' earnings last quarter?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by $0.14.

When did Aardvark Therapeutics IPO?

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

When did the company's lock-up period expire?

Aardvark Therapeutics's lock-up period expired on Tuesday, August 12th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are Aardvark Therapeutics' major shareholders?

Top institutional investors of Aardvark Therapeutics include Adage Capital Partners GP L.L.C. (0.81%), Geode Capital Management LLC (0.63%), Bank of America Corp DE (0.04%) and New York State Common Retirement Fund (0.03%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends.

How do I buy shares of Aardvark Therapeutics?

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $32.80
• High Price Target: $50.00
• Low Price Target: $19.00
• Potential Upside/Downside: +235.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.04
• Quick Ratio: 14.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.31 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 21,697,000
• Free Float: N/A
• Market Cap: $211.98 million
• Optionable: N/A
• Beta: N/A